Serum periostin is associated with type 2 immunity in severe asthma

Mats W. Johansson, Michael D. Evans, Gina M. Crisafi, Cécile T.J. Holweg, John G. Matthews, Nizar N. Jarjour

Research output: Contribution to journalArticlepeer-review

27 Scopus citations
Original languageEnglish (US)
Pages (from-to)1904-1907.e2
JournalJournal of Allergy and Clinical Immunology
Volume137
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Bibliographical note

Funding Information:
Disclosure of potential conflict of interest: M. W. Johansson and M. D. Evans have received research support from the National Institutes of Health (NIH). C. T. J. Holweg is employed by Genentech. J. G. Matthews is employed by and has stock/stock options in Roche. N. N. Jarjour has received research support from the NIH (grant nos. P01HL088584 and U10HL109168) and consultancy fees from Asthmatx, Genentech, and Teva Pharmaceuticals. G. M. Crisafi declares that she has no relevant conflicts of interest.

Funding Information:
This study was supported in part by NIH grant nos. R01 HL069116 and U10 HL109168, General Clinical Research Center (grant no. M01 RR03186 ), and Clinical and Translational Science Award from the NIH (grant no. UL1 RR025011 ).

Funding Information:
Disclosure of potential conflict of interest: M. W. Johansson and M. D. Evans have received research support from the National Institutes of Health (NIH). C. T. J. Holweg is employed by Genentech. J. G. Matthews is employed by and has stock/stock options in Roche. N. N. Jarjour has received research support from the NIH (grant nos. P01HL088584 and U10HL109168) and consultancy fees from Asthmatx, Genentech, and Teva Pharmaceuticals. G. M. Crisafi declares that she has no relevant conflicts of interest. Letter to the editor

Cite this